Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 2/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.44 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.43 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | CHUK | O15111 | 1/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 13/20 | 0.38 |
| ▸ | AKT1 | P31749 | 6/20 | 0.38 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.36 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27919686 | 0.89 | TET2 (0.54) | TET2TET1ALDH1A1CSNK2A2CSNK2B | |
| SCHEMBL12466645 | 0.76 | PIM1 (0.52) | PIM1PIM3TET2TET1TTK | |
| SCHEMBL16713378 | 0.75 | HTR4 (0.47) | RPS6KB1 | |
| SCHEMBL29377248 | 0.75 | RPS6KB1 (0.36) | PIM1IKBKBCHUKTTKPIM2 | |
| SCHEMBL1559078 | 0.75 | RPS6KB1 (0.36) | PIM1IKBKBCHUKTTKPIM2 | |
| Hydrochloric Acid SCHEMBL1560043 | 0.74 | RPS6KB1 (0.35) | PIM1IKBKBCHUKTTKPIM2 | |
| SCHEMBL3265420 | 0.73 | RPS6KB1 (0.43) | ALDH1A1RPS6KB1AKT1PKN1PKN2 | |
| SCHEMBL29589055 | 0.72 | ALDH1A1 (0.43) | IKBKBCHUKALDH1A1ATMRPS6KB1 | |
| SCHEMBL15173466 | 0.72 | ALDH1A1 (0.43) | IKBKBCHUKALDH1A1ATMRPS6KB1 | |
| SCHEMBL16713377 | 0.72 | PIM1 (0.43) | PIM1PIM3TET2TET1IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668190-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2013-12-04 | — | — | EP | claimed |
| WO-2012101032-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-08-02 | — | — | WO | claimed |
| US-9309253-B2 | Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-04-12 | — | — | US | disclosed |
| US-20150141408-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-05-21 | — | — | US | disclosed |
| US-8975267-B2 | Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2015-03-10 | — | — | US | disclosed |
| EP-2668190-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2013-12-04 | — | — | EP | disclosed |
| US-20130296305-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-11-07 | — | — | US | disclosed |
| WO-2012101032-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141408-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K6 | PIM1 522/4885PIM3 595/4885TET2 1604/4885 |
| US-20130296305-A1 | TRICYCLIC PYRROLO DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K5 | PIM1 514/4885PIM3 670/4885TET2 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.